Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05790096
Other study ID # FILBLAU1022
Secondary ID
Status Not yet recruiting
Phase Phase 3
First received
Last updated
Start date May 2023
Est. completion date December 2024

Study information

Verified date January 2023
Source Blau Farmaceutica S.A.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Randomized Study of the Clinical Efficacy and Safety of Filgrastine® in Patients with Breast Cancer Treated with Myelotoxic Chemotherapy. Primary Objective: to evaluate the activity and safety of Filgrastine® in Brazilian patients undergoing adjuvant treatment for breast cancer, with the frequency of grade 4 neutropenia in the first cycle of chemotherapy as the primary endpoint. Secondary Objectives: - Frequency of febrile neutropenia during treatment; - Frequency of neutropenia of any degree in the first cycle; - Frequency of hospitalization during treatment; - Duration of grade 4 neutropenia in the first treatment cycle; - Toxicity during treatment; - Immunogenicity throughout treatment. All endpoints will be descriptively analyzed in both groups of patients. Study design Randomized (2:1), open-label, multicenter study. Chemotherapy will be given on the first day of each cycle of treatment, for a maximum of four to eight cycles, depending on the regimen, patients whose chemotherapy treatment is prolonged beyond this period being withdrawn from the study. Patients will be evaluated through laboratory tests, including complete blood count, biochemistry and anti-filgrastim antibodies.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 60
Est. completion date December 2024
Est. primary completion date June 2024
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: - Provision of the Free and Informed Consent Form by written; - Female sex; - Age between 18 and 75 years old; - Diagnosis of breast cancer confirmed by cytology or histopathology; - Disease in stages II or III, according to the classification tumor-node-metastasis (TNM); - Indication of chemotherapy with full dose of one of the regimens eligible; - Performance status of 0 or 1; - Appropriate body functions (absolute neutrophil count [CAN] =1,500/mm³; platelet count =150,000/mm³; serum creatinine =1.2 mg/dL; bilirubin and transaminases =1.5 times the upper limit of normal). Exclusion Criteria: - Previous use of chemotherapy; - Previous use of filgrastim; - Prediction of prophylactic or therapeutic use of antibiotics, antifungals or antivirals in the first cycle of chemotherapy; - Previous radiotherapy involving the pelvis or radiotherapy from any site within the last 6 weeks prior to randomization; - History of bone marrow transplantation (as a recipient); - Presence of other neoplasms; - Presence of severe co-morbidities; - Recent (<6 months) or planned participation in other studies clinical trials involving drugs of any nature or in studies of any form of intervention; - Known intolerance or allergy to any of the components the filgrastim formulations evaluated in the study; - Pregnancy or lactation (patients of childbearing potential must have a negative serological pregnancy test dated within 7 days prior to randomization).

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
Granulokine
Granulokine is presented in boxes containing vials containing 1,0 mL of solution for injection and 300µg of filgrastim.
Filgrastine
Filgrastine is presented in boxes containing vials containing 1,0 mL of solution for injection and 300µg of filgrastim.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Blau Farmaceutica S.A.

Outcome

Type Measure Description Time frame Safety issue
Primary frequency of grade 4 neutropenia in the first cycle of chemotherapy in the group of patients treated with Filgrastine® 1 month
Secondary Frequency of febrile neutropenia during treatment; maximum 5 months
Secondary Frequency of neutropenia of any degree in the first cycle; 1 month
Secondary Frequency of hospitalization during treatment; maximum 5 months
Secondary Duration of grade 4 neutropenia in the first treatment cycle 1 month
Secondary Adverse event monitoring Any adverse event that occurs from Treatment Visit 1 (first day of medication) onwards will be followed through to the Final Visit or until your resolution of the event, whichever is later maximum 5 months
Secondary assessment of Immunogenicity throughout treatment by antigenic radiometric tests or ELISA The immunogenicity of filgrastim will be evaluated by antigenic radiometric tests or ELISA (enzyme-linked immunosorbant assay) to detect the formation of anti-G-CSF antibodies. All information will be recorded in the clinical form of the study. maximum 5 months
See also
  Status Clinical Trial Phase
Recruiting NCT04681911 - Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer Phase 2
Terminated NCT04066790 - Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer Phase 2
Completed NCT04890327 - Web-based Family History Tool N/A
Completed NCT03591848 - Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility N/A
Recruiting NCT03954197 - Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients N/A
Terminated NCT02202746 - A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer Phase 2
Active, not recruiting NCT01472094 - The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
Completed NCT06049446 - Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
Withdrawn NCT06057636 - Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study N/A
Recruiting NCT05560334 - A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations Phase 2
Active, not recruiting NCT05501769 - ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer Phase 1
Recruiting NCT04631835 - Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer Phase 1
Completed NCT04307407 - Exercise in Breast Cancer Survivors N/A
Recruiting NCT03544762 - Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation Phase 3
Terminated NCT02482389 - Study of Preoperative Boost Radiotherapy N/A
Enrolling by invitation NCT00068003 - Harvesting Cells for Experimental Cancer Treatments
Completed NCT00226967 - Stress, Diurnal Cortisol, and Breast Cancer Survival
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT06019325 - Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy N/A
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2